The comparative biopharmaceutical study of febuxostat solid dosage forms

Mikhail V. Larsky , Denis S. Zolotykh , Aleksei S. Chiriapkin , Vladislav V. Vernikovsky

For citation:

Abstract

Aim. Biopharmaceutical assessment of various solid dosage forms (capsules and coated tablets) of febuxostat formulations including comparison of excipients used in these dosage forms, disintegration pathways under static conditions, and dissolution kinetic profiles.

Methods. The Azurix® coated tablets and Podagrel hard gelatin capsules containing 80 mg of febuxostat were the object of the study. The model of disintegration under static conditions was used to assess disintegration of the dosage forms. Quantification of febuxostat in the samples diring the comparative study of dissolution kinetics was performed by high-performance liquid chromatography.

Results. When assessing morphological changes of dosage forms in the static model developed to simulate gastric environment, various desintegration patterns and rates confirmed by the differences in the qualitative composition of the excipients used were defined for these dosage forms. The comparative kinetics study showed different rates of febuxostat release from the studied dosage forms.

Conclusion. The findings demonstrate a significant impact of the excipient composition on the behavior of dosage forms in the body environment, particularly on the dosage form desintegration, which in turn defines the rate and degree of the active ingredient release. Thus, the test shows pronounced differences in biopharmaceutical parameters, capable of affecting the studied drugs bioavailability, between two febuxostat dosage forms.

Key words: febuxostat, coated tablets, capsules, in vitro release, disintegration under static conditions, high-performance liquid chromatography

References

1. Петрова М.С., Мазуров В.И., Инамова О.В. Фебуксостат для лечения хронической гиперурикемии у пациентов, страдающих подагрой. Медицинский Совет. 2017; 17: 114–22. DOI: 10.21518/2079-701X-2017-17-114-122 [Petrova M.S., Mazurov V.I., Inamova O.V. Febuksostat dlia lecheniia khronicheskoi giperurikemii u patsientov, stradaiushchikh podagroi. Meditsinskii Sovet. 2017; 17: 114–22. DOI: 10.21518/2079-701X-2017- 17-114-122 (in Russian).]

2. Молчанова О.В., Бритов А.Н., Платонова Е.В. Значение повышенного уровня мочевой кислоты в развитии и профилактике хронических неинфекционных заболеваний. Профилактическая медицина. 2020; 23 (2): 102–8. DOI: 10.17116/profmed20202 3021102 [Molchanova O.V., Britov A.N., Platonova E.V. Znachenie povyshennogo urovnia mochevoi kisloty v razvitii i profilaktike khronicheskikh neinfektsionnykh zabolevanii. Profilakticheskaia meditsina. 2020; 23 (2): 102–8. DOI: 10.17116/profmed20202 3021102 (in Russian).]

3. Подпалова О.В., Деев А.Д., Журова О.Н. и др. Повышенный уровень мочевой кислоты как независимый фактор риска развития артериальной гипертензии (по данным 5-летнего проспективного исследования). Кардиология в Беларуси. 2019: 11 (4): 567–75. [Podpalova O.V., Deev A.D., Zhurova O.N. et al. Povyshennyi uroven' mochevoi kisloty kak nezavisimyi faktor riska razvitiia arterial'noi gipertenzii (po dannym 5-letnego prospektivnogo issledovaniia). Kardiologiia v Belarusi. 2019: 11 (4): 567–75 (in Russian).]

4. Ильиных Е.В., Владимиров С.А., Елисеев М.С. Фебуксостат в терапии подагры: от теории к практике. Современная ревматология. 2017; 11 (4): 83–8. DOI: 10.14412/1996-7012-2017-4-83-88 [Il'inykh E.V., Vladimirov S.A., Eliseev M.S. Febuksostat v terapii podagry: ot teorii k praktike. Sovremennaia revmatologiia. 2017; 11 (4): 83–8. DOI: 10.14412/1996-7012-2017-4-83-88 (in Russian).]

5. Kamel B, Graham GG, Stocker SL et al. A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. Br J Clin Pharmacol 2020; 86: 2486–96. DOI: 10.1111/bcp.14357

6. Kamel B, Graham GG, Williams KM et al. Clinical pharmacokinetics and pharmacodynamics of febuxostat. Clin Pharmacokinet 2017; 56: 459–75. DOI: 10.1007/s40262-016-0466-4

7. Berardi A, Bisharat L, Quodbach J et al. Advancing the understanding of the tablet disintegration phenomenon – An update on recent studies. International Journal of Pharmaceutics 2021; 598. DOI: 10.1016/j.ijpharm.2021.120390

8. Deng L, Fu Y. Seeing Is Believing: Time-Lapse Macro-Imaging of Morphological Changes of Solid Dosages as a Teaching and Research Tool. Pharmaceutical Research 2022; 39: 1019–24. DOI: 10.1007/ s11095-022-03271-5

9. Malallah O, Rashid Z, Li CL et al. Digital Image Disintegration Analysis: A Novel Quality Control Method for Fast Disintegrating Tablets. AAPS PharmSciTech 2021; 22 (219). DOI: 10.1208/s12249-021- 02080-0

10. Алексеев К.В., Кедик С.А., Блынская Е.В. и др. Фармацевтическая технология. Твердые лекарственные формы. Под ред. С.А. Кедика. М.: Изд-во ЗАО «Институт фармацевтических технологий», 2011. [Alekseev K.V., Kedik S.A., Blynskaia E.V. et al. Farmatsevticheskaia tekhnologiia. Tverdye lekarstvennye formy. Pod red. S.A. Kedika. Moscow: Izd-vo ZAO "Institut farmatsevticheskikh tekhnologii', 2011 (in Russian).]

11. Алексеев К.В., Кедик С.А., Блынская Е.В. и др. Фармацевтическая технология. Таблетки. Под ред. С.А. Кедика. М.: ЗАО ИФТ, 2015. [Alekseev K.V., Kedik S.A., Blynskaia E.V. et al. Farmatsevticheskaia tekhnologiia. Tabletki. Pod red. S.A. Kedika. Moscow: ZAO IFT, 2015 (in Russian).]

12. Ураков А.Л., Николенко В.Н., Решетников А.П. и др. Физико-химические характеристики таблеток: факторы местного раздражающего действия. Фармация. 2019; 68 (8): 52–6. DOI: 10.29296/25419218-2019-08-09 [Urakov A.L., Nikolenko V.N., Reshetnikov A.P. et al. Fiziko-khimicheskie kharakteristiki tabletok: faktory mestnogo razdrazhaiushchego deistviia. Farmatsiia. 2019; 68 (8): 52–6. DOI: 10.29296/25419218- 2019-08-09 (in Russian).]

13. Растворение для твердых дозированных лекарственных форм. Т. 2. Государственная фармакопея Российской Федерации XIV изд. ОФС.1.4.2.0014.15. М., 2018. С. 2164–82. URL: https://femb.ru/ record/pharmacopea14 [Rastvorenie dlia tverdykh dozirovannykh lekarstvennykh form. T. 2. Gosudarstvennaia farmakopeia Rossiiskoi Federatsii XIV izd. OFS.1.4.2.0014.15. Moscow, 2018. P. 2164–82. URL: https://femb.ru/ record/pharmacopea14 (in Russian).]

14. ФС «Фебуксостат, таблетки» (проект). URL: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/053/199/orig inal/ФС_Фебуксостат__таблетки_08.12.2020.docx?1607683123 [FS "Febuksostat, tabletki" (proekt). URL: https://static-0.minzdrav. gov.ru/system/attachments/attaches/000/053/199/original/FS_Febuksostat__tabletki_08.12.2020.docx?1607683123 (in Russian).]

15. Правила проведения исследований биоэквивалентности лекарственных средств Евразийского экономического союза (утв. Решением Совета Евразийской экономической комиссии от 03.11.2016 №85; в ред. Решения Совета Евразийской экономической комиссии от 04.09.2020 №67). URL: https://www.alta.ru/tamdoc/16sr0085/ [Pravila provedeniia issledovanii bioekvivalentnosti lekarstvennykh sredstv Evraziiskogo ekonomicheskogo soiuza (utv. Resheniem Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 №85; v red. Resheniia Soveta Evraziiskoi ekonomicheskoi komissii ot 04.09.2020 №67). URL: https://www.alta.ru/tamdoc/16sr0085/ (in Russian).]

16. Sheskey PJ, Cook WG, Cable CG. Handbook of pharmaceutical excipients. Eighth edition. London: Pharmaceutical Press, 2017.

17. Руководство по экспертизе лекарственных средств. Том III. М.: Полиграф-Плюс, 2014. С. 217–24. [Rukovodstvo po ekspertize lekarstvennykh sredstv. Tom III. Moscow: Poligraf-Plius, 2014. P. 217–24 (in Russian).]

For citation:For citation: Larsky M.V., Zolotykh D.S., Chiriapkin A.S., Vernikovsky V.V. The comparative biopharmaceutical study of febuxostat solid dosage forms. Clinical review for general practice. 2022; 6: 78–95. DOI: 10.47407/kr2022.3.4.0012090p

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice